PwPepwise

Sermorelin

Growth Hormone

a.k.a. Geref

GHRH 1-29 fragment

Sermorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), a natural signal produced in the brain.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Diagnostic (provocative GH stimulation test)1 mcg/kg—IntravenousInjected directly into a vein.—
Therapeutic (pediatric GH deficiency)30 mcg/kg/dayTwice dailySubcutaneousInjected just under the skin, into the fat layer.36 mos
Combination secretagogue regimen (adult/hypogonadal men, off-label)100 mcg3× daily—134 days

Approximate values pulled from the research — double-check before dosing.

§01Summary

Sermorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), a natural signal produced in the brain that tells the pituitary gland to release growth hormone (GH). By activating the same receptor as the body's own GHRH, sermorelin stimulates the pituitary to secrete GH in a physiologically patterned way, rather than introducing GH directly from outside the body.

In children with growth hormone deficiency, once-daily sermorelin at bedtime has been reported to nearly double height velocity over six months, with growth rates sustained through twelve months of treatment2. Sermorelin has also been widely used as a diagnostic tool: a single intravenous dose appears to reliably provoke GH secretion, helping clinicians identify GH deficiency in both children and adults10. In combination with arginine or the GH-releasing peptide GHRP-6, sermorelin may offer diagnostic accuracy comparable to the insulin tolerance test, with a more favorable tolerability profile1. In hypogonadal men, a multi-secretagogue regimen including sermorelin has been reported to raise IGF-1 levels significantly over several months of treatment13. Sermorelin is generally well tolerated, with transient facial flushing and injection-site discomfort being the most commonly reported side effects10.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the amino-terminal fragment of endogenous human growth hormone-releasing hormone (hGRH 1-44), specifically the sequence hGRF(1-29)NH2. This truncated fragment retains full biological activity at the pituitary GHRH receptor (GHRHR), a Gs-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor binding activates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP), which in turn activates protein kinase A and triggers both acute GH secretion and, with repeated stimulation, upregulation of somatotroph cell proliferation and GH gene expression. The downstream effect is pulsatile release of endogenous GH into the systemic circulation, preserving the physiological feedback architecture of the GH/IGF-1 axis.

Native sermorelin has a plasma half-life of approximately 10–20 minutes in humans, attributable to rapid enzymatic cleavage primarily at the N-terminal dipeptide bond8. This short half-life necessitates either frequent dosing or strategic timing relative to the endogenous nocturnal GH surge, forming the pharmacological rationale for once-daily bedtime subcutaneous administration in therapeutic protocols2. PEGylation strategies targeting lysine residues at positions 12 and 21 of the GRF sequence have been investigated as a means of extending circulating half-life; mono-PEGylated conjugates with PEG5000 chains at these sites appear to retain high receptor binding affinity and produce superior pharmacodynamic GH responses compared to the unmodified peptide in preclinical models8.

The magnitude of GH response to sermorelin is modulated by the endogenous somatostatin tone at the hypothalamic-pituitary interface. Studies in children demonstrate that exogenous GH administration significantly blunts subsequent sermorelin-stimulated GH secretion — consistent with somatostatin-mediated negative auto-feedback — whereas sermorelin pretreatment itself does not inhibit subsequent somatotroph responsiveness to a second sermorelin dose4. This suggests that GHRH-induced GH release may be relatively insensitive to short-loop somatostatin feedback under certain conditions, with implications for tachyphylaxis risk during chronic sermorelin therapy.

Estrogen appears to potentiate the IGF-1 response to GH secretagogue regimens containing sermorelin; co-administration of aromatase inhibitors or selective estrogen receptor modulators has been associated with attenuated IGF-1 increases13, indicating a modulatory role for estrogenic tone in downstream GH axis signaling. Physiological states associated with altered hypothalamic somatostatin tone — such as high-altitude hypoxia5 or weight-loss-related hypothalamic amenorrhea6 — are associated with exaggerated GH responses to sermorelin, reflecting enhanced somatotroph sensitivity rather than direct peptide effects. Sermorelin crosses the placenta negligibly, with cord serum concentrations undetectable following maternal intravenous administration at term9.

§04Evidence & efficacy

Evidence base
123Studies
24Human
0Animal

In growth hormone-deficient children, once-daily subcutaneous sermorelin at 30 mcg/kg has been reported to nearly double mean height velocity, from approximately 4.1 cm/year at baseline to 8.0 cm/year at six months, with a sustained rate of 7.2 cm/year at twelve months2. Approximately 74% of evaluable children were classified as good responders at six months2, and bone age advancement remained proportional to height age gain, with a ratio not significantly different from 1.02. In children with chronic renal failure, sermorelin at approximately 26 mcg/kg/day has been reported to increase height velocity from 3.8 to 8.0 cm/year in approximately half of treated patients14.

As a diagnostic agent, sermorelin combined with GHRP-6 appears to provide diagnostic concordance with the insulin tolerance test and may offer superior discriminatory power between GH-deficient and non-GH-deficient patients in cranially irradiated populations1. IGF-1 levels appear non-discriminative in this setting, supporting the use of dynamic stimulation testing over static IGF-1 measurement1.

In a multi-secretagogue combination regimen including sermorelin, GHRP-2, and GHRP-6, IGF-1 levels were reported to increase by approximately 50% in compliant hypogonadal men over a mean of 134 days13, though the contribution of sermorelin specifically cannot be isolated from this combination protocol.

Preliminary computational analyses have identified sermorelin as a candidate with predicted sensitivity in recurrent high-grade glioma through potential cell cycle and immune pathway modulation12, an area where experimental investigation is actively emerging.

Children with GH deficiency who show inadequate growth response to sermorelin appear to respond well when transitioned to recombinant GH, and a lower peak GH response to provocative GHRH testing may predict a better subsequent response to exogenous GH therapy11.

§05Safety

Sermorelin has been reported to be well tolerated across both single-dose diagnostic and repeated daily therapeutic administration. The most consistently described adverse effects are transient facial flushing and pain or discomfort at the subcutaneous injection site, both of which appear mild and self-limiting10. No serious systemic adverse events were reported in the pediatric growth studies2,10, and no adverse changes in standard biochemical panels, fasting glucose, or IGF-1 generation beyond expected therapeutic ranges were observed in the 12-month pediatric cohort2. Injection site reactions were noted as the reason for one child's withdrawal from a sermorelin trial, highlighting that local tolerability can occasionally affect adherence11.

In pregnant women at term, sermorelin administration produced only a marginal, non-significant pituitary GH response, consistent with physiological suppression in late pregnancy, and no transplacental passage of the peptide was detected9. In cranially irradiated patients, the GHRH plus GHRP-6 combination offered a practical safety advantage over the insulin tolerance test, which was contraindicated in one patient due to epilepsy1.

In children with chronic renal failure, renal function remained generally stable during treatment, though two patients on conservative management showed a moderate rise in serum creatinine, suggesting that renal function monitoring is appropriate in this population14. No drug interaction data are formally reported; however, concurrent estrogen-modulating agents (aromatase inhibitors, tamoxifen) appear to attenuate IGF-1 responses to secretagogue combinations containing sermorelin13.

§06History

Sermorelin was developed following the isolation and characterization of hypothalamic growth hormone-releasing factor (GRF) in the early 1980s, when research groups identified the full 44-amino-acid sequence of human GHRH from pancreatic tumor tissue. Structure-activity studies rapidly established that the amino-terminal 29-residue fragment, hGRF(1-29)NH2, retained complete biological potency at the pituitary GHRHR, enabling synthesis of a shorter, more tractable therapeutic molecule.

Through the late 1980s and 1990s, sermorelin (marketed as Geref by Serono) was evaluated in both diagnostic and therapeutic contexts. It received regulatory approval in the United States as a diagnostic agent for assessing somatotroph function and subsequently as a treatment for idiopathic GH deficiency in children. Multi-center international studies through the mid-to-late 1990s documented significant height velocity improvements in GH-deficient children with once-daily bedtime dosing2, establishing the clinical proof-of-concept for GHRH-based growth promotion. Comparative and mechanistic studies in the same era characterized its utility as a provocative test agent, including its application in cranially irradiated patients1 and special pediatric populations such as chronic renal failure14.

A pivotal moment in sermorelin's regulatory history came in July 2008, when EMD Serono discontinued Geref in the United States, eliminating the GHRH-arginine stimulation test from routine US clinical practice and prompting reassessment of alternative GH stimulation protocols7. Analytical detection methods for sermorelin in anti-doping contexts have continued to develop into the 2020s15, while computational drug repurposing research has more recently flagged sermorelin as a candidate for investigation in recurrent glioma12.

§07References